Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 240

Sort by

Sort Order Select

Journal Articles

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Blood blood.2025030151.

https://doi.org/10.1182/blood.2025030151

Published: 2025

Includes: Supplemental data

Journal Articles

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Blood (2025) 146 (Supplement 1): 5521.

https://doi.org/10.1182/blood-2025-5521

Published: 2025

Journal Articles

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Blood (2025) 146 (Supplement 1): 1812.

https://doi.org/10.1182/blood-2025-1812

Published: 2025

Journal Articles

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Philippe Armand, Seung Tae Lee, Wojciech Jurczak, Don Stevens, Sylvain Choquet, Herve Ghesquieres, Lalita Norasetthada, Antonio Pinto, Güray Saydam, Heng Zhou, Nishitha Reddy, Rushdia Yusuf, Muhit Ozcan

Blood (2025) 146 (Supplement 1): 3745.

https://doi.org/10.1182/blood-2025-3745

Published: 2025

Journal Articles

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Ryan Lynch, David Russler-Germain, Joseph Schroers-Martin, Alison Moskowitz, Reid Merryman, Azra Borogovac, Hongyan Du, Heather Rasmussen, Ranjana Advani, Ash Alizadeh, Philippe Armand, Nancy Bartlett, Alex Herrera, Matthew Mei, Sarah Rutherford, David Kurtz, Ted Gooley, Jenna Voutsinas, Ajay Gopal

Blood (2025) 146 (Supplement 1): 5408.

https://doi.org/10.1182/blood-2025-5408

Published: 2025

Journal Articles

Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

Ioulia Vogiatzi, Emily Sumpena, Arsh Patel, Heather Walker, Rafaella Tringale, Robert Redd, Philippe Armand, Reid Merryman, Mark Murakami

Blood (2025) 146 (Supplement 1): 1790.

https://doi.org/10.1182/blood-2025-1790

Published: 2025

Journal Articles

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 464.

https://doi.org/10.1182/blood-2025-464

Published: 2025

Journal Articles

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy

Blood (2025) 146 (Supplement 1): 940.

https://doi.org/10.1182/blood-2025-940

Published: 2025

Journal Articles

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Blood (2025) 146 (Supplement 1): 664.

https://doi.org/10.1182/blood-2025-664

Published: 2025

Journal Articles

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

Blood (2025) 146 (Supplement 1): 3602.

https://doi.org/10.1182/blood-2025-3602

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

Blood (2025) 146 (Supplement 1): 3594.

https://doi.org/10.1182/blood-2025-3594

Published: 2025

Journal Articles

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Blood (2025) 146 (Supplement 1): 5377.

https://doi.org/10.1182/blood-2025-5377

Published: 2025

Journal Articles

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Jennifer Brown, Robert Black, Hang Phan, Katherine Chapis, Samantha Pazienza, Sandra Re, Svitlana Tyekucheva, Inhye Ahn, Matthew S Davids, Lars van der Veen, Michael Lahn, Philippe Armand

Blood (2025) 146 (Supplement 1): 3913.

https://doi.org/10.1182/blood-2025-3913

Published: 2025

Journal Articles

Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma

Emily Sumpena, Ioulia Vogiatzi, Arsh Patel, Heather Walker, Jenna Mahns, Robert Redd, Philippe Armand, Reid Merryman, Mark Murakami

Blood (2025) 146 (Supplement 1): 5344.

https://doi.org/10.1182/blood-2025-5344

Published: 2025

Journal Articles

Introduction to a review series on follicular lymphoma: solved or insoluble problem?

Philippe Armand

Blood (2025) 146 (15): 1739–1740.

https://doi.org/10.1182/blood.2025030824

Published: 2025

Journal Articles

Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness

Philippe Armand

Blood (2025) 145 (7): 653–654.

https://doi.org/10.1182/blood.2024027684

Published: 2025

Journal Articles

Frontline management of mantle cell lymphoma

Christine E. Ryan, Philippe Armand, Ann S. LaCasce

Blood (2025) 145 (7): 663–672.

https://doi.org/10.1182/blood.2023022352

Published: 2025

Journal Articles

The current landscape of frontline large B-cell lymphoma trials

David Qualls, Philippe Armand, Gilles Salles

Blood (2025) 145 (2): 176–189.

https://doi.org/10.1182/blood.2023023789

Published: 2025

Journal Articles

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Blood (2024) 144 (24): 2490–2502.

https://doi.org/10.1182/blood.2024024381

Published: 2024

Includes: Supplemental data

Journal Articles

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Saurabh Yadav, Sumbul Jawed Khan, Binu Kandathilparambil Sasi, Elizabeth F. Cohen, Kiyomi Mashima, Hannah Cormier, Stacey M. Fernandes, Samantha J. Shupe, Roberta Santos Azevedo, Mariia Mikhaleva, Philippe Armand, David C. Fisher, Matthew S. Davids, Inhye E. Ahn, Michael Y. Tolstorukov, Mark A. Murakami, Jennifer R. Brown

Blood (2024) 144 (Supplement 1): 4611.

https://doi.org/10.1182/blood-2024-207527

Published: 2024

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin lymphoma

Outcomes of CD20xCD3 bispecific antibody therapy in adult patients with Relapsed/Refractory transformed indolent lymphoma

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Phase 2/3 trial of zilovertamab vedotin plus standard of care in relapsed/ refractory diffuse large B-cell lymphoma: Updated analysis of waveline-003

Precise-HL trial: Personalized reduction of chemotherapy intensity through ctdna evaluation in advanced Hodgkin lymphoma

Immune cell dynamics following rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma

Rituximab and epcoritamab as first-line therapy for patients with high-tumor burden follicular lymphoma: Results of a multicenter phase II trial

Live-cell pick-seq (LiP-Seq): Interrogating ultra-rare Mantle Cell Lymphoma MRD after CD19-targeted CAR T-cell therapy

Phase I/II study of acalabrutinib, venetoclax, and obinutuzumab in patients with relapsed/refractory and previously untreated Mantle Cell Lymphoma (MAVO)

Glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with high-tumor burden follicular lymphoma: First results of a multicenter phase II trial

EO2463 (EO) peptide immunotherapy combined with rituximab (R) for first-line treatment of low-tumor burden follicular lymphoma (FL): A feasibility evaluation in Study EONHL1-20/sidney (NCT04669171)

EO2463 (EO) peptide immunotherapy in patients (pts) with newly diagnosed asymptomatic follicular lymphoma (FL) and marginal zone lymphoma (MZL): Study EONHL1-20/sidney (NCT04669171) primary endpoint lugano objective response analysis

Roginolisib (IOA-244), an orally bioavailable, selective PI3Kδ inhibitor, in combination with venetoclax and rituximab in patients with relapsed chronic lymphocytic leukemia (CLL)

Immune population changes after glofitamab and obinutuzumab (GLOBIN) as first-line therapy for patients with follicular lymphoma and marginal zone lymphoma

Introduction to a review series on follicular lymphoma: solved or insoluble problem?

Introduction to a review series on mantle cell lymphoma: sands shifting in the darkness

Frontline management of mantle cell lymphoma

The current landscape of frontline large B-cell lymphoma trials

Baseline immune state and T-cell clonal kinetics are associated with durable response to CAR-T therapy in large B-cell lymphoma

Clonal Evolution during Dual B Cell Receptor Pathway Inhibitor Therapy with Acalabrutinib and Umbralisib in CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only